HomeCompareBMY vs NKE

BMY vs NKE: Dividend Comparison 2026

BMY yields 4.17% · NKE yields 3.16%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NKE wins by $1.73M in total portfolio value· pulled ahead in Year 2
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
NKE
NKE
● Live price
3.16%
Share price
$51.24
Annual div
$1.62
5Y div CAGR
66.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.85M
Annual income
$1,337,341.87
Full NKE calculator →

Portfolio growth — BMY vs NKE

📍 NKE pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYNKE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + NKE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
NKE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
NKE
Annual income on $10K today (after 15% tax)
$268.74/yr
After 10yr DRIP, annual income (after tax)
$1,136,740.59/yr
At 15% tax rate, NKE beats the other by $1,102,890.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + NKE for your $10,000?

BMY: 50%NKE: 50%
100% NKE50/50100% BMY
Portfolio after 10yr
$986.1K
Annual income
$688,582.76/yr
Blended yield
69.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NKE right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
NKE
Analyst Ratings
1
Strong
42
Buy
23
Hold
4
Sell
Consensus: Buy
Price Target
$75.35
+47.1% upside vs current
Range: $62.00 — $110.00
Altman Z
3.8
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
NKE buys
0
No recent congressional trades found for BMY or NKE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYNKE
Forward yield4.17%3.16%
Annual dividend / share$2.49$1.62
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%66.3%
Portfolio after 10y$120.5K$1.85M
Annual income after 10y$39,823.66$1,337,341.87
Total dividends collected$91.0K$1.78M
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$62.73$75.35

Year-by-year: BMY vs NKE ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrNKE PortfolioNKE Income/yrGap
1$11,271$571.12$11,226$525.77+$45.00BMY
2← crossover$12,884$824.20$12,929$917.32$45.00NKE
3$14,993$1,206.32$15,476$1,642.01$483.00NKE
4$17,839$1,797.27$19,614$3,054.78$1.8KNKE
5$21,826$2,738.11$27,004$6,017.26$5.2KNKE
6$27,643$4,289.31$41,770$12,875.77$14.1KNKE
7$36,534$6,955.64$75,648$30,954.02$39.1KNKE
8$50,861$11,770.13$168,071$87,127.77$117.2KNKE
9$75,402$20,980.23$480,693$300,856.83$405.3KNKE
10$120,504$39,823.66$1,851,684$1,337,341.87$1.73MNKE

BMY vs NKE: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

NKEConsumer Discretionary

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells men's, women's, and kids athletic footwear, apparel, equipment, and accessories worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. In addition, it sells a line of performance equipment and accessories comprising bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. The company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel. Additionally, it licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. The company sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

Full NKE Calculator →
📬

Get this BMY vs NKE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.